Link Health Group Ltd.

Primary objective To evaluate the tolerability and safety of umomostat bisulfate capsules (LH011) combined with gemcitabine hydrochloride (GEM) in the treatment of patients with locally advanced/metastatic pancreatic cancer, and to determine the MTD of LH011 combined with GEM, so as to provide a recommended dose for the next clinical trial. Secondary objectives To evaluate the pharmacokinetic characteristics of LH011 and its metabolites; To evaluate the efficacy of LH011 combined with GEM in the treatment of locally advanced/metastatic pancreatic cancer; To evaluate the effect of LH011 on tumor markers (CA19-9) and uPA-related markers (such as D-dimer).

To evaluate the safety and tolerability of single and continuous administration of LH031 for relapsed/refractory multiple myeloma; to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), and to recommend a reasonable dosing regimen for later clinical studies.

Primary objective: To evaluate the tolerability and safety of single combined with multiple intra-articular injections of LH021 for the treatment of primary knee osteoarthritis. Secondary objectives: (1) To determine the systemic pharmacokinetic parameters of the drug after intra-articular injection of LH021 (2) To evaluate the effect of LH021 on target knee joint function and pain Exploratory objectives: To explore the relationship between biomarkers and drug efficacy